Oncology
Renal Cell Cancer
0
Pipeline Programs↗
4
Active Trials↗
5
Companies Involved↗
Renal Cell Cancer is an early-stage landscape with 0 programs across 5 companies. The most active players are Pfizer, Astellas, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
31
clinical trials
Completed14 · 45%
Terminated8 · 26%
Unknown status3 · 10%
Active, not recruiting2 · 6%
Not yet recruiting2 · 6%
Suspended1 · 3%
Other1 · 3%
Clinical Trials
Trial Activity
31 trials
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
Not yet recruiting·—·Phase 2·NCT07037004·62 enrolled
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
Not yet recruiting·—·Phase 2·NCT07226544·31 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)